CEO transition and positive FTX-6058 Phase 1b data; cash runway into late 2024

Fulcrum Therapeutics, Inc.

CEO Bryan Stuart departs; Robert Gould, former CEO/board member, appointed interim CEO effective Jan 3, 2023.
FTX-6058 granted FDA Fast Track for SCD; Phase 1b shows HbF increases up to 9.5% at 6 mg, generally well tolerated.
Plan to complete enrollment in Phase 3 REACH trial of losmapimod in FSHD during 2H 2023.
Cash runway expected to fund operations into late 2024; next FTX-6058 data update expected in Q4 2023.
Phase 1b enrollment ongoing in 12 mg cohort; dose-dependent HbF increase observed across adherent patients.

item 2.02 item 8.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Bryan Stuart

president, chief executive officer and Class II director

FULC · Fulcrum Therapeutics, Inc.

Effective: 2023-01-02
Successor: Robert J. Gould
Filed: January 4, 2023, 6:59 PM ET

On January 2, 2023, Bryan Stuart and Fulcrum Therapeutics, Inc., or Fulcrum, mutually agreed that he would transition from his role as president, chief executive officer and as Class II director

Appointed (interim)

Robert J. Gould

Interim President and Chief Executive Officer

FULC · Fulcrum Therapeutics, Inc.

Effective: 2023-01-03
Filed: January 4, 2023, 6:59 PM ET

On January 3, 2023, the board of directors of Fulcrum, or the Board, appointed Robert J. Gould, former chief executive officer and president and current Class III director, as interim president and chief executive officer and as Fulcrum’s principal executive officer, effective January 3, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bryan Stuart changed role as president, chief executive officer and Class II director at Fulcrum Therapeutics, Inc..

Action: transitioned
Role: president, chief executive officer and Class II director

Exact text from the filing

On January 2, 2023, Bryan Stuart and Fulcrum Therapeutics, Inc., or Fulcrum, mutually agreed that he would transition from his role as president, chief executive officer and as Class II director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert J. Gould was appointed as Interim President and Chief Executive Officer at Fulcrum Therapeutics, Inc..

Action: appointed
Role: Interim President and Chief Executive Officer

Exact text from the filing

On January 3, 2023, the board of directors of Fulcrum, or the Board, appointed Robert J. Gould, former chief executive officer and president and current Class III director, as interim president and chief executive officer and as Fulcrum’s principal executive officer, effective January 3, 2023.

View on SEC.gov

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-001193

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.